Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SAN FRANCISCO--(BUSINESS WIRE)-- Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven obesity care and treatments more ...

That partnership will see Hims & Hers offer Novo Nordisk’s weight-loss drug Wegovy through its platform. Here’s what you need to know. Hims & Hers will offer weight-loss drug Wegovy Hims ...

Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies from marketing or selling cheaper, unapproved versions of the drugmaker's blockbuster weight loss drug Wegovy ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, Human Mixtard, among other older insulin brands in India. Human Mixtard ...

Alphabet shares surged following the company’s first-quarter earnings report, which revealed strong double-digit growth in revenue and profit. The performance was propelled by continued strength in ...

You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide ...

Novo Nordisk will invest around $1 billion to expand its production site in Montes Claros, Brazil, marking one of the largest pharmaceutical investments in the nation’s history. The company’s ...

Riyadh, Saudi Arabia – Novo Nordisk, a leading global healthcare company, today announced the signing of a Memorandum of Understanding (MOU) with Lifera, a biopharmaceutical company owned by the Saudi ...

Abbott is the marketing partner for Novo’s insulin. Confirming the development, a Novo Nordisk spokesperson said, “In order to meet increasing patient demand and ensure a stable supply of our ...

Not to be outdone, chief rival Novo Nordisk revealed Saturday that it has already filed for FDA approval of an oral formulation of its own blockbuster, semaglutide, for overweight and obesity. Finally ...